Mode
Text Size
Log in / Sign up
N/A N=40 Treatment

Venous Insufficiency and Neuromuscular Stimulation

Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
geko device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Imperial College London
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage Change of Haemodynamic Flow
34.8; 62.8; 9; 14.8; -14.2; 28.1
SECONDARY
Improvement in Venous Symptoms
SECONDARY
Leg Volume

Summary

The investigators will be evaluating the immediate and longer term effect of treatment with a medical device on the symptoms of chronic venous disease.

Eligibility Criteria

Group 1

  • Inclusion criteria - 18+ years old, 17<BMI<30
  • Exclusion criteria - Heart/lung/kidney failure, pregnancy, diagnosis of peripheral vascular disease, previous VTE, ABPI<0.9, active infection, previous leg fracture or metal implant in leg

Group 2

  • Inclusion criteria - 18+ years old, 17<BMI<30, clinical diagnosis of superficial venous insufficiency (CEAP C2-6) confirmed with duplex US
  • Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI<0.9, active infection, previous leg fracture or metal implant in leg

Group 3

  • Inclusion criteria - 18+ years old, 17<BMI<30, clinical diagnosis of deep venous insufficiency (CEAP C2-6) confirmed with duplex US
  • Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI<0.9, active infection, previous leg fracture or metal implant in leg

Group 4

  • Inclusion criteria - 18+ years old, 17<BMI<30, clinical diagnosis of deep venous obstruction confirmed with duplex US
  • Exclusion criteria - Heart/lung/kidney failure, pregnancy, ABPI<0.9, active infection, previous leg fracture or metal implant in leg
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02137499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search